Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Nektar Therapeutics (NKTR) PT Raised to $35 at Jefferies; Plans '181 NDA 2 Years Early
November 8, 2017 8:28 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $23.00) while maintaining a Buy rating following Q3 results.
Analyst David Steinberg said the big news was NKTR disclosed that they are now planning to file an NDA for 181 in Apr... More
